Precision BioSciences (DTIL) announced that the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status
- Precision BioSciences announces additional PBGENE-DMD preclinical data
- Precision BioSciences: Strong Buy Rating Based on Promising Gene Editing Innovations and Market Positioning
- Precision granted Rare Pediatric Disease Designation for PBGENE-DMD
- Precision BioSciences: Promising Gene Editing Platform Targets Chronic HBV and DMD with Strategic Focus